Frazier Life Sciences Management, L.P.

CIK 0001892134 · PALO ALTO, CA · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source

Frazier Life Sciences Management, L.P. reported 41 positions worth $4.59B as of June 30, 2026 (13F filed August 14, 2026). Largest holding: MIRM (19.6%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$4.59B
2026 Q2
Positions
41
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
73.6%
Est. Net Flow (Q)
2026 Q2
10 / 41 positions shown
#SymbolCompanyTypeValue% Port.Shares1YYTD
1MIRMMIRUM PHARMACEUTICALS INCSH$899.1M19.58%7,679,684
2NAMSNEWAMSTERDAM PHARMA COMPANYSH$613.0M13.35%18,088,902
3ERASERASCA INCSH$457.5M9.96%24,975,188
4MBXMBX BIOSCIENCES INCSH$367.2M8.00%6,652,013
5ARQTARCUTIS BIOTHERAPEUTICS INCSH$258.9M5.64%9,874,511
6TRVITREVI THERAPEUTICS INCSH$185.4M4.04%9,939,447
7KRYSKRYSTAL BIOTECH INCSH$178.9M3.90%481,307
8MAZEMAZE THERAPEUTICS INCSH$150.2M3.27%5,032,915
9PHATPHATHOM PHARMACEUTICALS INCSH$135.3M2.95%12,466,489
10PVLAPALVELLA THERAPEUTICS INC NESH$134.8M2.94%882,400

The free plan shows the top 10 positions. The remaining 31 positions, the full portfolio and quarter changes unlock with Pro.

Pro Feature

This section is exclusive to Fundocap Pro. Full holdings tables, consensus trades, ownership analysis, backtests and exports unlock with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does Frazier Life Sciences Management, L.P. hold as of Q2 2026?

Frazier Life Sciences Management, L.P. reported 41 positions worth $4.59B in its Q2 2026 13F filing. Largest positions: MIRM (19.6%), NAMS (13.3%), ERAS (10.0%), MBX (8.0%) and ARQT (5.6%).

What did Frazier Life Sciences Management, L.P. buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Frazier Life Sciences Management, L.P. sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.